Velan Capital Investment Management
Latest statistics and disclosures from Velan Capital Investment Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, TARA, STRO, EVMN, MPLT, and represent 50.28% of Velan Capital Investment Management's stock portfolio.
- Added to shares of these 10 stocks: TENX (+$8.0M), IMMX (+$6.4M), STRO, AVR, XNCR, CTMX, LYEL, ESPR, ABVX, RCKT.
- Started 12 new stock positions in NMRA, AVR, LYEL, KPTI, NSRX, RCKT, QNRX, XNCR, ARTV, KLRS. MGNX, XLO.
- Reduced shares in these 10 stocks: CDTX (-$24M), LNTH, MLYS, RAPT, TERN, SNDX, TRVI, EVMN, KZIA, AVTX.
- Sold out of its positions in CDTX, LNTH, PYXS, RAPT, TERN, TRVI, Trevi Therapeutics, VTYX, Xilio Therapeutics.
- Velan Capital Investment Management was a net seller of stock by $-13M.
- Velan Capital Investment Management has $160M in assets under management (AUM), dropping by -7.39%.
- Central Index Key (CIK): 0001848809
Tip: Access up to 7 years of quarterly data
Positions held by Velan Capital Investment Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Velan Capital Investment Management
Velan Capital Investment Management holds 49 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 20.3 | $33M | 101k | 322.19 |
|
|
| Protara Therapeutics Com Stk (TARA) | 9.3 | $15M | 2.8M | 5.21 |
|
|
| Sutro Biopharma Com Shs (STRO) | 8.0 | $13M | +64% | 512k | 24.91 |
|
| Evommune Com Shs (EVMN) | 6.4 | $10M | -11% | 446k | 22.99 |
|
| Maplight Therapeutics (MPLT) | 6.3 | $10M | -5% | 493k | 20.33 |
|
| Tenax Therapeutics Com New (TENX) | 5.8 | $9.3M | +600% | 583k | 15.99 |
|
| Abivax Sa Sponsored Ads (ABVX) | 5.4 | $8.6M | +14% | 77k | 111.35 |
|
| Heron Therapeutics (HRTX) | 4.4 | $7.0M | 8.8M | 0.80 |
|
|
| Immix Biopharma (IMMX) | 4.2 | $6.7M | +2014% | 740k | 9.11 |
|
| Esperion Therapeutics (ESPR) | 3.0 | $4.7M | +42% | 1.7M | 2.74 |
|
| Edesa Biotech Com New (EDSA) | 2.7 | $4.3M | +20% | 828k | 5.23 |
|
| Anteris Technologies Global (AVR) | 2.4 | $3.9M | NEW | 700k | 5.55 |
|
| Inspiremd (NSPR) | 2.1 | $3.4M | -2% | 2.1M | 1.63 |
|
| Xencor (XNCR) | 1.9 | $3.0M | NEW | 250k | 12.06 |
|
| Avalo Therapeutics Com New (AVTX) | 1.7 | $2.8M | -29% | 185k | 14.93 |
|
| Eupraxia Pharmaceuticals (EPRX) | 1.6 | $2.5M | 352k | 7.24 |
|
|
| Cytomx Therapeutics (CTMX) | 1.6 | $2.5M | +575% | 540k | 4.70 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 1.6 | $2.5M | 472k | 5.29 |
|
|
| Jasper Therapeutics Com New (JSPR) | 1.5 | $2.3M | 2.7M | 0.88 |
|
|
| Rezolute Com New (RZLT) | 1.4 | $2.3M | 750k | 3.05 |
|
|
| Lyell Immunopharma Com New (LYEL) | 1.3 | $2.0M | NEW | 102k | 20.06 |
|
| Profound Med Corp Com New (PROF) | 1.2 | $1.9M | 286k | 6.48 |
|
|
| Miragen Therapeutics (VRDN) | 1.1 | $1.8M | +5% | 91k | 19.56 |
|
| Rocket Pharmaceuticals (RCKT) | 0.7 | $1.1M | NEW | 295k | 3.58 |
|
| Kazia Therapeutics Sponsored Ads (KZIA) | 0.6 | $1.0M | -54% | 135k | 7.44 |
|
| Nasus Pharma Ord Shs (NSRX) | 0.5 | $798k | NEW | 359k | 2.22 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.4 | $560k | NEW | 85k | 6.60 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.3 | $408k | 6.5k | 62.70 |
|
|
| Protagonist Therapeutics (PTGX) | 0.2 | $390k | 3.7k | 105.40 |
|
|
| Ovid Therapeutics (OVID) | 0.2 | $355k | 160k | 2.22 |
|
|
| Mineralys Therapeutics (MLYS) | 0.2 | $298k | -92% | 11k | 27.09 |
|
| Context Therapeutics (CNTX) | 0.2 | $262k | 100k | 2.62 |
|
|
| Nurix Therapeutics (NRIX) | 0.2 | $248k | 16k | 15.50 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.2 | $244k | +100% | 26k | 9.39 |
|
| Syndax Pharmaceuticals (SNDX) | 0.1 | $234k | -92% | 10k | 23.36 |
|
| Precision Biosciences Com New (DTIL) | 0.1 | $220k | +100% | 40k | 5.50 |
|
| Immunome (IMNM) | 0.1 | $219k | 10k | 21.87 |
|
|
| Design Therapeutics (DSGN) | 0.1 | $213k | 20k | 10.64 |
|
|
| Artiva Biotherapeutics (ARTV) | 0.1 | $161k | NEW | 25k | 6.44 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $156k | NEW | 80k | 1.95 |
|
| Replimune Group (REPL) | 0.1 | $153k | +33% | 20k | 7.65 |
|
| Larimar Therapeutics (LRMR) | 0.1 | $149k | 33k | 4.50 |
|
|
| Xilio Therapeutics (XLO) | 0.1 | $120k | NEW | 14k | 8.41 |
|
| Kalaris Therapeutics (KLRS) | 0.1 | $104k | NEW | 18k | 5.77 |
|
| Pmv Pharmaceuticals (PMVP) | 0.1 | $91k | +108% | 73k | 1.24 |
|
| Macrogenics (MGNX) | 0.1 | $87k | NEW | 30k | 2.89 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $84k | NEW | 15k | 5.57 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.0 | $73k | 45k | 1.62 |
|
|
| Gossamer Bio (GOSS) | 0.0 | $23k | 70k | 0.33 |
|
Past Filings by Velan Capital Investment Management
SEC 13F filings are viewable for Velan Capital Investment Management going back to 2021
- Velan Capital Investment Management 2026 Q1 filed May 15, 2026
- Velan Capital Investment Management 2025 Q4 filed Feb. 13, 2026
- Velan Capital Investment Management 2025 Q3 filed Nov. 14, 2025
- Velan Capital Investment Management 2025 Q2 filed Aug. 14, 2025
- Velan Capital Investment Management 2025 Q1 filed May 15, 2025
- Velan Capital Investment Management 2024 Q4 filed Feb. 14, 2025
- Velan Capital Investment Management 2024 Q3 filed Nov. 14, 2024
- Velan Capital Investment Management 2024 Q2 filed Aug. 14, 2024
- Velan Capital Investment Management 2024 Q1 filed May 14, 2024
- Velan Capital Investment Management 2023 Q3 filed Nov. 13, 2023
- Velan Capital Investment Management 2023 Q2 filed Aug. 11, 2023
- Velan Capital Investment Management 2023 Q1 filed May 15, 2023
- Velan Capital Investment Management 2022 Q4 filed Feb. 13, 2023
- Velan Capital Investment Management 2022 Q3 filed Nov. 14, 2022
- Velan Capital Investment Management 2022 Q2 filed Aug. 15, 2022
- Velan Capital Investment Management 2022 Q1 filed May 16, 2022